Medical Advocates for Social Justice
Delavirdine (Rescriptor)
 
Journal Citations


General Reports
Pharmacokinetics
Drug/Drug Interactions
Resistance
Adverse Events
 Efficacy



 
Delavirdine Main Page ARV Drugs Main Page Home Page      
Last Update:  December 08, 2014
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 Perinatal Journal Data are integrated with Perinatal Conference Data in the Perinatal Data Page
Pediatric Journal Data are integrated with Pediatric  Conference Data in the Pediatric Data Page
General Reports
         
 
Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and
releasing stavudine, delavirdine and saquinavir.
 Kuo YC, Chung CY.
Colloids Surf B Biointerfaces. 2011
Abstract

Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing
a diketoacid functionality into delavirdine.
Wang Z, Vince R.  
Bioorg Med Chem. 2008 Feb 8
Abstract
 
Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by
polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid
nanoparticles.
 Kuo YC, Su FL
Int J Pharm. 2007 Mar 12
 Abstract
Pharmacokinetics
         
 
Population Pharmacokinetics of Delavirdine and N-Delavirdine in HIV-Infected Individuals.
Smith PF, Dicenzo R, Forrest A, et al
Clin Pharmacokinet. 2005;44(1):99-109.
 Abstract

Pharmacokinetics of Ritonavir and Delavirdine in Human Immunodeficiency Virus-Infected Patients.
Shelton MJ, Hewitt RG, Adams J, et al.
Antimicrob Agents Chemother 2003 May;47(5):1694-1699
 Abstract

  
Drug-Drug Interactions
         
  Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir.
Tran JQ, Petersen C, Garrett M, et al.
Clin Pharmacol Ther 2002 Dec;72(6):615-626
 Abstract		  
Resistance
 
  Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility
of patient isolates to delavirdine.
Uhlmann EJ, Tebas P, Storch GA ,et al 
J Clin Virol. 2004 Nov;31(3):198-203.
 Abstract
 
  FULL-TEXT ARTICLE
 Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus
Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a
Randomized, Comparative Phase III Trial
Joly V , Moroni M, Concia E,
Antimicrob Agents Chemother  2000 Nov;44(11):3155-3157
  Paper
Adverse Events
 
  Delavirdine malabsorption in HIV-infected subjects with spontaneous
gastric hypoacidity.
Shelton MJ, Hewitt RG, Adams JM, et al.
J Clin Pharmacol 2003 Feb;43(2):171-9
 Abstract
Efficacy
 

FULL-TEXT ARTICLE
 Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus
Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a
Randomized, Comparative Phase III Trial
Joly V, Moroni M, Concia E, et al;
 Antimicrob Agents Chemother 2000 Nov;44(11):3155-3157
 Paper

FULL-TEXT ARTICLE
 ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human
Immunodeficiency Virus Activity of Delavirdine Monotherapy.
Para MF, Meehan P, Holden-Wiltse J, et al.
Antimicrob Agents Chemother 1999 Jun;43(6):1373-1378
 Paper
FULL-TEXT ARTICLE
 Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in
Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of
Delavirdine Monotherapy (ACTG 260)
Demeter LM, Shafer RW, Meehan PM, et al.
Antimicrob Agents Chemother 2000 Mar;44(3):794-797
 Paper
Delavirdine Main Page ARV Drugs Main Page Home Page      

Delavirdine Journal Citations